Oncologix Tech Inc (OCLG)

[SPM555]

Emergen Research has a 250 page report on the hereditary genetic testing market and the huge growth potential. I highly encourage people check this out because these guys thought enough of us to give us a very substantial mention.



https://www.emergenresearch.com/press-release/global-hereditary-genetic-testing-market

To be clear, this merger was announced in May of 2022 and the company has gone radio silent. The retail market believes this is a nothing burger and no update = the merger was a scam. This $5500 report sees it otherwise and gave it a very big shout out in 250 page industry analysis, and to be double clear this isn't a chintzy penny stock pump report. Read the link and you'll see what I mean. The fact that these guys spelled out our merger (article came out on Jan 3 fyi) and thought to mention such a teenie tiny entirely under the radar stock and company speaks volumes.

On 2 May 2022, Oncologix Tech, Inc., which is an OTC Market company, and DNAGO.Ai, a biopharmaceutical firm offering clinical genetic testing on all 20,000+ genes covering 7,000+ rare genetic illnesses at an accessible price for patients in need with DNAGO's AI System, announced they have agreed into a legally binding business combination agreement. After this merger is completed, OCLG will become DNAGO, and its common stock and warrants are anticipated to continue being traded on the OTC Market under the ticker letters OCLG.

The quality of information in this article leads me to strongly believe their due diligence indicates this merger to be a real deal and very much happening - and the fact that they thought to mention it so prominently indicates it has huge implications.